

**DISCLOSURE STATEMENT PURSUANT TO  
THE PINK BASIC DISCLOSURE GUIDELINES**

**STRATEGIC ASSET LEASING, INC.**

A Wyoming Corporation

**1740H Dell Range Blvd. #166 Cheyenne,  
WY 82009**

(Company's Address)

**(828) 888-8828**

(Company's telephone number)

**None**

(Company's Website)

**sm@ceres.vg** (Company's email)

**7371 – Computer Programming Services**

(Company's SIC Code)

**QUARTERLY REPORT**

For the Period Ending September 30, 2021  
(the "Reporting Period")

As of November 15, 2021, the number of shares outstanding of our Common Stock was:

1,044,861,360 shares

As of Date At End of Previous Reporting Period, the number of shares outstanding of our Common Stock was:

-0- shares

As of December 31, 2020, the Most Recent Fiscal Year End Reporting Period, the number of shares outstanding of our Common Stock was:

-0- shares

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☒

No: ☐

Indicate by check mark whether the company's shell company status has changed since the previous reporting period:

Yes: ☐

No: ☒

Indicate by check mark whether a Change in Control of the company has occurred over this reporting period:

Yes: ☒

No: ☐

**Explanatory Note:** The November 1, 2021 Agreement and Plan of Merger between the Company and ANEW Medical Inc. (ANEW) was treated as a reverse acquisition for financial statement reporting purposes. Accordingly, the ANEW's assets, liabilities and results of operations became the historical financial statements of the Company. Therefore, as noted above, the shares outstanding were -0- for the "Date At End of Previous Reporting Period previous report" and "December 31, 2020, the Most Recent Fiscal Year End Reporting Period".

## **PART A      GENERAL COMPANY INFORMATION**

### **Item 1.      Name of the issuer and its predecessor (if any).**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Strategic Asset Leasing Inc. from 10/02/2014 to present.

Mommoth Energy Group, Inc. from 05/22/2006 to 10/02/2014.

Vision Dynamics Inc. from 02/27/2006 to 05/22/2006.

Technigen Corp. from 08/02/2004 to 02/27/2006.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g., active, default, inactive):

The company was organized in Nevada on 08/02/2004 and re-domiciled to Wyoming on 03/05/2013. The company's standing is active in the state of Wyoming.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On December 14, 2020, the Company entered a Stock Purchase Agreement with Dr, Joseph Sinkule for 1,000,000 shares of the Company's Series C preferred stock. The purchase price was \$110,000. Jason Tucker, the Company's CEO, resigned from the Company and Mr. Simkule become the Company's CEO and sole director. The \$110,000 proceeds were used to repay the Company's promissory notes and accrued interest and compensate Mr. Tucker for his service to the Company. The transaction resulted in a change in control of the Company.

On November 1, 2021, the Company executed an Agreement and Plan of Merger with Anew Acquisition Corp ("ANEW"), including the wholly own subsidiaries ANEW Oncology, Inc. and Anew Gene Therapy Inc., whereby each issued and outstanding share of ANEW common stock was converted into the right to receive one-one hundredth (1/100) of a share of the Company's Series B preferred stock, par value \$.001 per share. On November 1, 2021, the total ANEW stock issued and outstanding was 40,525,000 shares which was converted into 405,250 shares of the Company's Series B preferred stock.

The Agreement and Plan of Merger between the Company and ANEW was treated as a reverse acquisition for financial statement reporting purposes. Accordingly, the ANEW's assets, liabilities and results of operations became the historical financial statements of the Company. The Company's name will be changed to ANEW Medical, Inc. The 1,044,861,360 outstanding shares of Company's common stock prior to the Agreement and Plan of Merger agreement, were considered to be shares issued upon the reverse acquisition.

The address(es) of the issuer's principal executive office:

1740H Dell Range Blvd. #166 Cheyenne, WY 82009

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the Company or any of its predecessors ever been in bankruptcy, receivership, or other similar proceeding in the past five years?

Yes: ☐

No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

Not applicable

**Item 2. Security Information.**

Trading Symbol:	LEAS
Exact title and class of securities outstanding:	Common Stock
CUSIP:	86270P1063
Par or Stated Value:	\$0.0001 par value
Total Shares Authorized:	1,500,000,000 as of November 15, 2021
Total Shares Outstanding:	1,044,861,360 as of November 15, 2021
Number of shares in Public Float:	1,039,540,345 as of November 15, 2021.
Total number of shareholders of record:	35 as of November 15, 2021.
Trading Symbol:	None
Exact title and class of securities outstanding:	Series B Preferred Stock (1)
CUSIP:	None
Par or Stated Value:	\$0.001 par value
Total Shares Authorized:	500,000 as of November 15, 2021
Total Shares Outstanding:	405,250 as of November 15, 2021
Trading Symbol:	None
Exact title and class of securities outstanding:	Series C Preferred Stock
CUSIP:	None
Par or Stated Value:	\$0.0001 par value
Total Shares Authorized:	5,000,000 as of November 15, 2021
Total Shares Outstanding:	1,000,000 as of November 15, 2021

- (1) On October 15, 2021, the Company designated 500,000 shares of Series B convertible preferred stock "Series B preferred stock". The holders of each share of the Series B preferred stock shall be entitled to receive dividends declared by the Board of Directors and conversion to 100 shares of the Company's common stock. In the event of a reverse common stock split, there will be no adjustment to the conversion of Series B preferred stock into shares of the Company's common stock.

The name and address of the Company's transfer agent is:

Name: Transfer Online, Inc.  
 Phone: (503) 227-2950  
 Email: info@transferonline.com

Is the Transfer Agent registered under the Exchange Act? Yes: ☒ No: ☐

### Item 3. Issuance History.

Disclosure under this Item 3 includes, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services.

#### A. Changes in the Number of Outstanding Shares.

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

<div> <div>Number of Shares Outstanding as of January 1, 2018:</div> <div>Opening Balance: Common: 644,861,360 Preferred: 1,000,000</div> </div>									
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at issuance	Were the shares issued at a discount to market price at the time of issuance? Yes or No	Individual/ Entity Shares were issued to (entities must have individual with voting/investment control disclosed).	Reason for share issuance (e.g., for cash or debit conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
2/5/2019	New Issuance	10,000,000	Common	1,000	No	Said Jabarian	Consulting (1)	Restricted	Section 4(a) (2)
4/22/2019	New Issuance	102,000,000	Common	10,200	No	Dennis Balbat	Consulting (2)	Restricted	Section 4(a) (2)
5/31/2019	New Issuance	4,000,000	Preferred	400	No	Dennis Balbat	Consulting (3)	Restricted	Section 4(a) (2)
2/27/2020	New Issuance	(10,000,000)	Common	(1,000)	No	Said Jabarian	Consulting (1)	Restricted	Section 4(a) (2)
2/28/2020	New Issuance	(102,000,000)	Common	(10,200)	No	Dennis Balbat	Consulting (2)	Restricted	Section 4(a) (2)
3/24/2020	New Issuance	(5,000,000)	Preferred	(500)	No	Dennis Balbat	Consulting (3)	Restricted	Section 4(a) (2)

4/27/2020	New Issuance	60,000,000	Common	72,000	No	Jason Tucker	Consulting (4)	Restricted	Section 4(a) (2)
7/29/2020	New Issuance	70,000,000	Common	392,000	No	Jason Tucker	Consulting (5)	Restricted	Section 4(a) (2)
8/7/2020	New Issuance	70,000,000	Common	189,000	No	Jason Tucker	Consulting (6)	Restricted	Section 4(a) (2)
9/25/2020	New Issuance	80,000,000	Common	344,000	No	Jason Tucker	Consulting (7)	Restricted	Section 4(a) (2)
10/7/2020	New Issuance	90,000,000	Common	216,000	No	Jason Tucker	Consulting (8)	Restricted	Section 4(a) (2)
10/16/2020	New Issuance	30,000,000	Common	54,000	No	Jason Tucker	Consulting (9)	Restricted	Section 4(a) (2)
12/14/2020	New Issuance	1,000,000	Preferred	110,000	No	Joseph Sinkule	Acquire control of the Company (10)	Restricted	Section 4(a) (2)
Shares Outstanding on September 30, 2021 (11)	Ending Balance: Common: 1,044,861,360 Preferred: 1,000,000								

Please note the following additional details, including footnotes to the table above:

- (1) On February 5, 2019, the Company issued 10,000,000 restricted shares of the Company's common Stock to Said Jabarian for services to the Company. The shares were valued at \$1,000 or \$0.0001 per share. On February 27, 2020, Mr. Jabarian returned the shares as the services were never rendered.
- (2) On April 22, 2019, the Company issued 102,000,000 restricted shares of the Company's common Stock to Dennis Balbat, the Company's former CEO, for services to the Company. The shares were valued at \$10,200 or \$0.0001 per share. On February 28, 2020, Mr. Balbat returned the shares as a condition of the change of Company control.
- (3) On May 31, 2019, the Company issued 4,000,000 shares of the Company's Series C preferred stock to Dennis Balbat, the Company's former CEO, for services to the Company. The shares were valued at \$400 or \$0.0001 per share. On March 24, 2020, Mr. Balbat returned 5,000,000 shares of the Company's Series C preferred stock including 1,000,000 shares issue in the year ended December 31, 2019, as a condition of the change of Company control.
- (4) On April 27, 2020, the Company issued 60,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$72,000 or \$0.0012 per share.
- (5) On July 29, 2020, the Company issued 70,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$392,000 or \$0.0056 per share.

(6) On August 7, 2020, the Company issued 70,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$189,000 or \$0.0027 per share.

(7) On September 25, 2020, the Company issued 80,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$344,000 or \$0.0043 per share.

(8) On October 7, 2020, the Company issued 90,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$216,000 or \$0.0024 per share.

(9) On October 16, 2020, the Company issued 30,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$54,000 or \$0.0018 per share.

(10) On December 14, 2020, the Company entered a Stock Purchase Agreement with Dr, Joseph Sinkule, the Company CEO for 1,000,000 shares of the Company's Series C preferred stock. The purchase price was \$110,000 or \$0.11 per share. The transaction resulted in change of control of the Company.

(11) The following shares were not issued as of September 30, 2021:

None

#### **B. Debt Securities, including Promissory and Convertible Notes.**

The chart below lists and describes all outstanding promissory notes, convertible promissory notes and any other debt instrument that may be converted into a class of the issuer's equity securities as of September 30, 2021.

Check this box if there are no outstanding promissory notes, convertible notes or debt arrangements: ☒

Please note the following additional details, including footnotes to the table above:

None

#### **Item 4. Financial Statements.**

A. The following financial statements were prepared in accordance with:

☒ U.S. GAAP  
☐ IFRS

B. The financial statements for this reporting period were prepared by:

Name: Rick Basse, CPA  
Title: Owner of Rick Basse Consulting, PLLC  
Relationship to Issuer: Accountant engaged by Company

The following financial statements described below are provided and incorporated by this reference for the most recent fiscal year or quarter:

- C. Consolidated Balance Sheets;
- D. Consolidated Statements of Operations;
- E. Statement of Changes in Shareholders' Equity
- F. Statement of Cash Flows;
- G. Financial Notes; and
- H. Audit letter, if audited (the Company was not Audited)

## **B BUSINESS INFORMATION**

### **Item 5. Issuer's Business, Products and Services.**

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

On October 15, 2021, the Company designated 500,000 shares of Series B convertible preferred stock "Series B preferred stock". The holders of each share of the Series B preferred stock shall be entitled to receive dividends declared by the Board of Directors and conversion to 100 shares of the Company's common stock. In the event of a reverse common stock split, there will be no adjustment to the conversion of Series B preferred stock into shares of the Company's common stock.

On November 1, 2021, the Company executed an Agreement and Plan of Merger with Anew Acquisition Corp ("ANEW"), including the wholly own subsidiaries ANEW Oncology, Inc. and Anew Gene Therapy Inc., whereby each issued and outstanding share of ANEW common stock was converted into the right to receive one-one hundredth (1/100) of a share of the Company's Series B preferred stock, par value \$.001 per share. On November 1, 2021, the total ANEW stock issued and outstanding was 40,525,000 shares which was converted into 405,250 shares of the Company's Series B preferred stock. As stated in the Agreement and Plan of Merger, each share of Series B preferred stock shall automatically be converted into a number of shares of Company's common Stock equal to the number of shares of Series B preferred stock being converted, multiplied by 100 on the date of the completion a reverse common stock split for an aggregate of 40,525,000 shares of the Company's common stock.

The Agreement and Plan of Merger between the Company and ANEW was treated as a reverse acquisition for financial statement reporting purposes. Accordingly, the ANEW's assets, liabilities and results of operations became the historical financial statements of the Company. The Company's name will be changed to ANEW Medical, Inc. The 1,044,861,360 outstanding shares of Company's common stock prior to the Agreement and Plan of Merger agreement, were considered to be shares issued upon the reverse acquisition.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Development Stage Company operating in the medical drug development industry.

B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of such entity's business, contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

On June 08, 2020 the Company formed a new subsidiary, Strategic Asset Holdings, LLC.



As of December 14, 2020 Dr. Joseph Sinkule is the Company's sole officer and director.

As of November 1, 2021, ANEW Oncology, Inc. and ANEW Gene Therapy Inc. became wholly own subsidiaries of the Company. ANEW has licensed rights in major world markets to life-saving biologic medicines and gene therapies that will be developed and commercialized by the Company and affiliates and/or corporate partners.

C. Describe the issuers' principal products or services, and their markets

Drug development industry.

## **Item 6. Issuer's Facilities.**

### **Description of Corporate Offices**

The company's sole officer and director is currently working remotely from his home office at no cost to the issuer until more adequate office space is required.

## **PART C MANAGEMENT STRUCTURE AND FINANCIAL INFORMATION**

### **Item 7. Officers, Directors and Control Persons.**

The table below provides information regarding any person or entity owning 5% or more of any class of the Company's equity securities as of November 15, 2021, as well as any officer, and any director of the Company, regardless of the number of shares owned. Also, if any listed person are corporate shareholders or entities, information is provided as to the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation of entity in the Note section.

Name of Officer/Director or Control Person	Affiliation with Company (e.g., Officer/Director/Owner of more than 5%)	Residential Address (City/State only)	Number of Shares owned	Share type/class	Ownership Percentage of Class Outstanding (1)	Note
Dr. Joseph Sinkule	Chief Executive Officer, Chief Financial Officer and Director	Goodyear, AZ	None 1,000,000	Common Series C Preferred	0% 100%	

Use the space below to provide any additional details, including footnotes to the table above

(1) As of November 15, 2021, issued and outstanding shares consisted of 1,044,861,360 shares of common stock, 1,000,000 shares of Series C preferred stock.

**Item 8. Legal/Disciplinary History.**

A. At no time have any of the persons listed above, in the past 10 years, been subject to any of the following:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended or vacated; or

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incident to the business, to which the issuer or any of its subsidiaries is a party or which any of their property is subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceeding known to be contemplated by governmental authorities.

NONE

**Item 9. Third Party Providers**

1.      Securities Counsel:   Paul Goodman, Esq.  
                                  Cyruli Shanks & Zizmor, LLP  
                                  420 Lexington Avenue  
                                  Suite 2320  
                                  New York, NY 10170  
                                  Phone no.: (917) 596-0965  
                                  Email: pgoodman@cszlaw.com
  
2.      Accountant:           Rick Basse, CPA  
                                  Rick Basse Consulting, PLLC  
                                  244 Majestic Oak Drive  
                                  New Braunfels, Texas 78132  
                                  Phone no.: (210) 347-0374  
                                  Email: rick.basse@gmail.com
  
3.      Investor Relations Consultant:  
                                  Shawn A. Mesaros  
                                  Managing Partner **Ceres BV**  
                                  Address: 9B, Atmel Building, 148 Des Voeux Road Central, Central Hong  
                                  Kong  
                                  Phone: (828) 800-8888  
                                  Email: sm@ceres.vg
  
4.      Other Service Providers:

The name(s) of other service provider(s), including counsel, advisor(s) or consultant(s) that assisted, advised, prepared or provided information with respect to this disclosure statement, or provided assistance or services to the Company during the Reporting Period are as follows:

Name: None

Firm:

Nature of Services:

Address:

Phone:

Email:

**Item 10. Issuer's Certifications.**

I, Dr, Joseph Sinkule, certify that:

1. I have reviewed this Quarterly Report of Strategic Asset Leasing Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statement, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: November 15, 2021.

Strategic Asset Leasing Inc.



By \_\_\_\_\_

Dr, Joseph Sinkule, Chief Executive  
Officer, Chief Financial Officer and Director

## **Exhibit A**

**STRATEGIC ASSET LEASING, INC.**  
1740H Dell Range Blvd. #166  
Cheyenne, WY 82009

### **Financial Statements and Notes For the Three and Nine-months Ended September 30, 2021 and 2020**

#### **Explanatory Note**

On November 1, 2021, the Company executed an Agreement and Plan of Merger with ANEW Medical Inc. (“ANEW”; “the Accounting Entity”). See Note 9 – Subsequent Events. The share exchange of the Company’s Series B preferred stock for the common stock of the Accounting Entity was treated as a reverse acquisition for financial statement reporting purposes with the Accounting Entity deemed the accounting acquirer and the Company deemed the accounting acquiree. Accordingly, the Accounting Entity’s assets, liabilities and results of operations became the historical financial statements of the Company. Since the acquisition shares were issued by the Company after September 30, 2021, no common stock is reported in the below financial statement and notes before September 30, 2021. On November 1, 2021, the Company had 1,044,861,360 common shares issued and outstanding and 405,205 shares of Series B preferred stock issued and outstanding.

**STRATEGIC ASSET LEASING, INC.**  
CONSOLIDATED BALANCE SHEETS (Unaudited)

	<u>September 30, 2021</u>	<u>December 31, 2020</u>
<b>ASSETS</b>		
Current assets:		
Cash	\$ -	\$ -
Prepaid expenses	6,281	-
Total current assets	<u>6,281</u>	<u>-</u>
<b>Total Assets</b>	<b>\$ <u>6,281</u></b>	<b>\$ <u>-</u></b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accents payable and accrued expenses	\$ -	\$ 1,137
Related party advances	12,461	-
Total current liabilities	<u>12,461</u>	<u>1,137</u>
Stockholders' equity (deficiency):		
Preferred stock Series C, \$0.0001 par value; 5,000,000 shares authorized; 1,000,000 issued and outstanding as of September 30, 2021 and December 31, 2020	100	100
Common stock, \$0.0001 par value; 1,500,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2021 and December 31, 2020	-	-
Additional paid in capital	16,773,143	16,773,143
Accumulated deficit	<u>(16,779,423)</u>	<u>(16,774,380)</u>
Total stockholders' equity (deficiency)	<u>(6,180)</u>	<u>(1,137)</u>
<b>Total Liabilities and Stockholders' equity</b>	<b>\$ <u>6,281</u></b>	<b>\$ <u>-</u></b>

The accompanying notes are an integral part of these financial statements.

**STRATEGIC ASSET LEASING, INC.**  
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

	For the Three Months Ended		For the Nine Months Ended	
	<u>September 30, 2021</u>	<u>September 30, 2020</u>	<u>September 30, 2021</u>	<u>September 30, 2020</u>
Operating expenses:				
Stock compensation expense	-	991,000	-	991,000
General and administrative	<u>3,907</u>	<u>14,068</u>	<u>5,043</u>	<u>44,843</u>
Total operating expenses	<u>3,907</u>	<u>1,005,068</u>	<u>5,043</u>	<u>1,035,843</u>
Net operating income (loss)	(3,907)	(1,005,068)	(5,043)	(1,035,843)
Other (income) expense:				
Interest expense	-	1,640	-	1,640
Interest accretion	-	37,008	-	37,008
Impairment expense	<u>-</u>	<u>30,000</u>	<u>-</u>	<u>30,000</u>
Total Other (income) expense	<u>-</u>	<u>68,648</u>	<u>-</u>	<u>68,648</u>
Loss before provision for taxes	(3,907)	(1,073,716)	(5,043)	(1,104,491)
Provision for income taxes	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Net income (loss)	<u>\$ (3,907)</u>	<u>\$ (1,073,716)</u>	<u>\$ (5,043)</u>	<u>\$ (1,104,491)</u>
Basic and diluted income (loss) per share	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>
Weighted average number of common shares outstanding - basic	1,044,861,360	798,230,925	1,044,861,360	735,985,448

The accompanying notes are an integral part of these financial statements.

**STRATEGIC ASSET LEASING, INC.**  
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - Unaudited

	Preferred Stock - Series C		Common Stock		Additional	Accumulated	Total
	Shares	Amount	Shares	Amount	Paid-In Capital	Deficit	Stockholders' Equity (Deficit)
<b><u>Three Months Ended September 30, 2020</u></b>							
Balance at June 30, 2020		\$	-	\$ -	\$ 15,348,569	\$ (15,395,543)	\$ (46,974)
Issuance of common stock for services			-	-	991,000		991,000
Debt discounts					53,675		53,675
Net loss, period ended September 30, 2020						(1,073,716)	(1,073,716)
Balance at September 30, 2020	-	\$ -	-	\$ -	\$ 16,393,244	\$ (16,469,259)	\$ (76,015)
<b><u>Nine Months Ended September 30, 2020</u></b>							
Balance at December 31, 2019	5,000,000	\$ 500	-	\$ -	\$ 15,362,255	\$ (15,364,768)	\$ (2,013)
Issuance of common stock for services			-	-	997,000		997,000
Shares of common and preferred cancelled or retired	(5,000,000)	(500)	-	-	(19,686)		(20,186)
Debt discounts					53,675		53,675
Net loss, period ended September 30, 2020						(1,104,491)	(1,104,491)
Balance at September 30, 2020	-	\$ -	-	\$ -	\$ 16,393,244	\$ (16,469,259)	\$ (76,015)
<b><u>Three Months Ended September 30, 2021</u></b>							
Balance at June 30, 2021	1,000,000	\$ 100	-	\$ -	\$ 16,773,143	\$ (16,775,516)	\$ (2,273)
Net loss, period ended September 30, 2021						(3,907)	(3,907)
Balance at September 30, 2021	1,000,000	\$ 100	-	\$ -	\$ 16,773,143	\$ (16,779,423)	\$ (6,180)
<b><u>Nine Months Ended September 30, 2021</u></b>							
Balance at December 31, 2020	1,000,000	\$ 100	-	\$ -	\$ 16,773,143	\$ (16,774,380)	\$ (1,137)
Net loss, period ended September 30, 2021						(5,043)	(5,043)
Balance at September 30, 2021	1,000,000	\$ 100	-	\$ -	\$ 16,773,143	\$ (16,779,423)	\$ (6,180)

The accompanying notes are an integral part of these financial statements.



# STRATEGIC ASSET LEASING, INC.

## Consolidated Statements of Cash Flow (Unaudited)

	For the Nine Months Ended	
	September 30, 2021	September 30, 2020
Cash flows from operating activities:		
Net income (loss)	\$ (5,043)	\$ (1,104,491)
Adjustments to reconcile net loss to net cash used in operating activities:		
Interest accretion	-	37,008
Stock based compensation	-	991,000
Impairment expense	-	30,000
Changes in operating assets and liabilities:		
Prepaid expenses	(6,281)	10,091
Accents payable and accrued expenses	(1,137)	31,892
Net cash provided by (used in) operating activities	(12,461)	(4,500)
Cash flows from investing activities:		
Purchase of equipment	-	(30,000)
Net cash used in investing activities	-	(30,000)
Cash flows from financing activities:		
Loan from principal director and CEO	-	34,500
Related party cash advances	12,461	-
Net cash provided by financing activities	12,461	34,500
Net increase (decrease) in cash	-	-
Cash - beginning of the year	-	-
Cash - end of the year	\$ -	\$ -
Supplemental disclosures:		
Interest paid	\$ -	\$ -
Income taxes	\$ -	\$ -

The accompanying notes are an integral part of these financial statements.

**Strategic Asset Leasing, Inc.**  
**Notes to Consolidated Financial Statements (Unaudited)**  
**September 30, 2021**

**NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION BASIS**

**Nature of organization & business**

i) Organization

The accompanying consolidated financial statements include Strategic Asset Leasing, Inc., formerly known as Mammoth Energy Group, Inc. ('LEAS' or the 'Company'), its wholly-owned subsidiaries and any majority controlling interests.

The Company was incorporated on February 27, 2006 under the laws of the State of Nevada with the aim of pursuing lithium mining. Prior to being domiciled in Nevada, the Company was a Canadian corporation known as Technigen Corporation. In March of 2013, management decided to change the domicile of the Company to Wyoming by filing articles of continuance on March 5, 2013, subsequently dissolving the Nevada corporation.

On February 4, 2019 William Lieberman issued 1,000,000 Preferred C shares to settle the June 5, 2016 note to Universal Marketing Concepts, making Mr. Bolbat majority shareholder and effecting a change of control.

In March of 2019, the Company and The New Auto Toy Store mutually agreed to forego the acquisition. The decision to cancel the transaction was due in part to a third-party finder, with knowledge of the pending acquisition, taking to social media and message boards throughout March and April and adversely impacting the transaction.

On April 3, 2019, the Company entered into a MOU with Marijuana Business and Marketing Network, a Southeast Asia company, to Joint Venture on sourcing and importing hemp-based products to the US.

In January 2020, due to regulatory and taxation hurdles, the Company abandoned the proposed Joint Venture to source and import hemp-based products from Southeast Asia.

On February 6, 2020 Denis Bolbat appointed Jason Tucker as CEO and resigned his position from the Company. Jason Tucker owns the Intellectual Property for a cash app “Add-On” source code that can be installed into existing Applications, allowing inner circle friends to share Currency and Crypto-Currency amongst one another in a fee free environment. Mr. Tucker has additional software, hardware, and source code currently under development and being reviewed for patenting.

On June 8, 2020 the Company formed a new subsidiary, Strategic Asset Holdings, LLC.

During August 2020, the Company approved an increase in the number of authorized common stock from 800,000,000 shares to 1,500,000,000 shares. Thereafter, the Company filed a Certificate of Amendment, with the state of Wyoming, increasing its authorized common stock from 800,000,000 shares to 1,500,000,000 shares.

On December 14, 2020, the Company entered a Stock Purchase Agreement with Dr. Joseph Sinkule for 1,000,000 shares of the Company's Series C preferred stock. The purchase price was \$110,000. Jason Tucker, the Company's CEO, resigned from the Company and Mr. Sinkule became the Company's CEO and sole director. The \$110,000 proceeds were used to repay the Company's promissory notes and accrued interest and compensate Mr. Tucker for his service to the Company. The transaction resulted in a change in control of the Company.

In accordance with Accounting Standards Codification (“ASC”) 915, Development Stage Entities, the Company is considered to be in the development stage, with limited operations since incorporating in the United States.

**Basis of Presentation**

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America.

**Use of Estimates**

In preparing financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheet and revenue and expenses in the statement of expenses. Actual results could differ from those estimates.

## **Reclassifications**

Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results of operations. In addition, certain prior year amounts from the restated amounts have been reclassified for consistency with the current period presentation.

## **Cash and Cash Equivalents**

For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

## **Concentrations of Risk**

Cash and cash equivalents deposited with financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC"). The Company did not hold cash in excess of FDIC insurance coverage at a financial institution as of September 30, 2021 and December 31, 2020.

## **Prepaid Expenses**

The Company considers all items incurred for future services to be prepaid expenses.

## **Property and equipment**

Property and equipment are recorded at cost and depreciated on the straight-line method over the estimated useful lives. Expenditures for normal repairs and maintenance are charged to expense as incurred. The cost and related accumulated depreciation of assets sold or otherwise disposed of are removed from the accounts, and any gain or loss is included in operations.

## **Valuation of Long-Lived and Intangible Assets**

We assess the impairment of long-lived and intangible assets periodically, or at least annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors considered important, which could trigger an impairment review, include the following: significant underperformance relative to historical or projected future cash flows; significant changes in the manner of use of the assets or the strategy of the overall business; and significant negative industry trends. When management determines that the carrying value of long-lived and intangible assets may not be recoverable, impairment is measured as the excess of the assets' carrying value over the estimated fair value. Management is not aware of any other impairment changes that may currently be required; however, we cannot predict the occurrence of events that might adversely affect the reported values in the future. At September 30, 2020, the Company wrote-off \$30,000 of equipment as impaired.

## **Derivative Financial Instruments**

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based derivative financial instruments, The Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

## **Fair Value Measurements**

In September 2006, the FASB issued ASC 820 (previously SFAS 157) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The provisions of ASC 820 were effective January 1, 2008.

As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observations of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The three levels of the fair value hierarchy defined by ASC 820 are as follows:

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.

Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management's best estimate of fair value.

The Company did not identify any assets or liabilities that are required to be adjusted on the balance sheet to fair value as of September 30, 2021 and December 31, 2020.

## **Revenue Recognition**

The Company recognizes revenue under ASU No. 2014-09, "*Revenue from Contracts with Customers (Topic 606)*," ("ASC 606"). The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services transferred to the customer.

### Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and service transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon delivery.

Bartering transactions represent the exchange of Company services for other services. These transactions are recorded at the estimated fair market value of the services provided or the fair value of the services received, whichever is most readily determinable. Revenue is recognized on bartering transactions and trade transactions when the services are provided. Expenses are recorded ratably over a period that estimates when the service received is utilized, or when the event occurs. Bartering transactions and trade revenues and expenses from continuing operations are included in revenue and cost of revenues, respectively.

## **Income taxes**

The Company's policy is to provide for deferred income taxes based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect when the differences are expected to reverse. The U.S. Tax Cuts and Jobs Act (TCJA) legislation reduces the U.S. federal corporate income tax rate from 35.0% to 21.0% and is effective June 22, 2018 for the Company. We did not provide any current or deferred U.S. federal income tax provision or benefit for any of the periods presented because we have experienced operating losses since inception. When it is more likely than not that a tax asset cannot be realized through future income the Company must allow for this future tax benefit. We provided a full valuation allowance on the net deferred tax asset, consisting of net operating loss carryforwards, because management has determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the carryforward period.

The Company is not aware of any uncertain tax position that, if challenged, would have a material effect on the financial statements for the nine-months ended September 30, 2021 or during the prior three years applicable under FASB ASC 740. We did not recognize any adjustment to the liability for uncertain tax position and therefore did not record any adjustment to the beginning balance of accumulated deficit on the consolidated balance sheet. The Company is in the process of filing all unfiled tax returns. All tax returns for the Company remain open for examination.

## **Basic and diluted net income per share**

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from common stock equivalents, such as stock issuable pursuant to convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. At September 30, 2021, the Company had no common stock equivalents.

## **Stock Compensation**

The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 718 and No. 505. After December 15, 2018, the scope of Topic 718, Compensation—Stock Compensation, was expanded to include share-based payments issued to nonemployees for goods and services. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period.

The Company uses the Black-Scholes-Merton valuation model for estimating the fair value of traded options and stock warrants. There were no stock warrants or stock options outstanding at September 30, 2021 and 2020, respectively.

The Company recorded stock-based compensation of \$-0- and \$991,000 for the three-months ended September 30, 2021 and 2020, respectively, and \$-0- and \$991,000 for the nine-months ended September 30, 2021 and 2020, respectively.

## **Related Parties**

The registrant follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.

Pursuant to Section 850-10-20 the Related parties include (a) affiliates of the registrant; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the registrant; (e) management of the registrant; (f) other parties with which the registrant may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

### Recently Issued Accounting Standards

In December 2019, the FASB issued ASU 2019-12, *Simplifying the Accounting for Income Taxes*, as part of its Simplification Initiative to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the effect ASU 2019-12 will have on the consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU 2020-06, *Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity*. ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, *Derivatives and Hedging*, or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. ASU 2020-06 also removes certain conditions that should be considered in the derivatives scope exception evaluation under Subtopic 815-40, *Derivatives and Hedging—Contracts in Entity’s Own Equity*, and clarify the scope and certain requirements under Subtopic 815-40. In addition, ASU 2020-06 improves the guidance related to the disclosures and earnings-per-share (EPS) for convertible instruments and contract in entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Board specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluation the impact this ASU will have on its consolidated financial statements.

Management believes recently issued accounting pronouncements will have no impact on the financial statements of the Company.

### NOTE 2 - GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred material recurring losses from operations. The Company has not generated material revenues since inception and has generated losses totaling \$16,779,423 since inception. In addition, the Company is experiencing a continuing operating cash flow deficiency. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

The consolidated financial statements do not contain any adjustments to reflect the possible future effects on the classification of assets or the amounts and classification of liability that may result should the Company be unable to continue as a going concern.

### NOTE 3 – PREPAID EXPENSES

Prepaid expenses consist of the following:

		<u>September</u> <u>30, 2021</u>		<u>December 31,</u> <u>2020</u>
OTC Market fees	\$	5,041	\$	-
Accounting consulting fees		1,240		-
	\$	6,281	\$	-

#### **NOTE 4 – NOTES PAYABLE**

The Company's three notes payable and related accrued interest for \$93,124 were paid off under the December 14, 2020 Stock Purchase Agreement with Dr, Joseph Sinkule, the Company's CEO. See *Note 4 – Equity Transactions* for a further discussion.

#### **NOTE 5 – EQUITY TRANSACTIONS**

The Company was established with two classes of stock, common stock – 1,500,000,000 shares authorized at a par value of \$0.0001 and Class C preferred stock 5,000,000 shares authorized at a par value of \$0.0001. During August 2020, the Company increased the authorized shares of common stock from 800,000,000 shares to 1,500,000,000 shares.

At September 30, 2021 and December 31, 2020, the Company issue and outstanding common stock was -0- shares and Class C preferred stock was 1,000,0000 shares. See Note 9 – Subsequent Events for a discussion of the reverse acquisition.

##### *Class C Preferred stock*

On May 31, 2019, the Company issued 4,000,000 shares of the Company's Series C preferred stock to Dennis Balbat, the Company's former CEO, for services to the Company. The shares were valued at \$400 or \$0.0001 per share. On March 24, 2020, Mr. Balbat returned 5,000,000 shares of the Company's Series C preferred stock including 1,000,000 shares issue in the year ended December 31, 2019, as a condition of the change of Company control

On December 14, 2020, the Company entered a Stock Purchase Agreement with Dr, Joseph Sinkule, the Company CEO, for 1,000,000 shares of the Company's Series C preferred stock. The purchase price was \$110,000 or \$0.11 per share. The \$110,000 proceeds were used to repay the Company's promissory notes and accrued interest and compensate the former CEO for his service to the Company. The transaction resulted in a change in control of the Company.

##### *Common Stock*

On February 5, 2019, the Company issued 10,000,000 restricted shares of the Company's common Stock to a consultant for services to the Company. The shares were valued at \$1,000 or \$0.0001 per share. On February 27, 2020, the consultant returned the shares as the services were never rendered.

On April 22, 2019, the Company issued 102,000,000 restricted shares of the Company's common Stock to Dennis Balbat, the Company's former CEO, for services to the Company. The shares were valued at \$10,200 or \$0.0001 per share. On February 28, 2020, the former CEO returned the shares as a condition of the change of Company control.

On April 27, 2020, the Company issued 60,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$72,000 or \$0.0012 per share.

On July 29, 2020, the Company issued 70,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$392,000 or \$0.0056 per share.

On August 7, 2020, the Company issued 70,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$189,000 or \$0.0027 per share.

On September 25, 2020, the Company issued 80,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$344,000 or \$0.0043 per share.

On October 7, 2020, the Company issued 90,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$216,000 or \$0.0024 per share.

On October 16, 2020, the Company issued 30,000,000 restricted shares of the Company's common Stock to Jason Tucker, the Company's former CEO, for services to the Company. The shares were valued at \$54,000 or \$0.0018 per share.

## **NOTE 6 – SUBSEQUENT EVENTS**

On October 15, 2021, the Company designated 500,000 shares of Series B convertible preferred stock “Series B preferred stock”. The holders of each share of the Series B preferred stock shall be entitled to receive dividends declared by the Board of Directors and conversion to 100 shares of the Company’s common stock. In the event of a reverse common stock split, there will be no adjustment to the conversion of Series B preferred stock into shares of the Company’s common stock.

On November 1, 2021, the Company executed an Agreement and Plan of Merger with Anew Acquisition Corp (“ANEW”), including the wholly own subsidiaries ANEW Oncology, Inc. and Anew Gene Therapy Inc., whereby each issued and outstanding share of ANEW common stock was converted into the right to receive one-one hundredth (1/100) of a share of the Company’s Series B preferred stock, par value \$.001 per share. On November 1, 2021, the total ANEW stock issued and outstanding was 40,525,000 shares which was converted into 405,250 shares of the Company’s Series B preferred stock. As stated in the Agreement and Plan of Merger, each share of Series B preferred stock shall automatically be converted into a number of shares of Company’s common Stock equal to the number of shares of Series B preferred stock being converted, multiplied by 100 on the date of the completion a reverse common stock split for an aggregate of 40,525,000 shares of the Company’s common stock.

The Agreement and Plan of Merger between the Company and ANEW was treated as a reverse acquisition for financial statement reporting purposes. Accordingly, the ANEW’s assets, liabilities and results of operations became the historical financial statements of the Company. The Company’s name will be changed to ANEW Medical, Inc. The 1,044,861,360 outstanding shares of Company’s common stock prior to the Agreement and Plan of Merger agreement, were considered to be shares issued upon the reverse acquisition.

The Company evaluated all events or transactions that occurred through November 15, 2021. During this period, the Company did not have any other material recognizable subsequent events.